期刊
WILEY INTERDISCIPLINARY REVIEWS-RNA
卷 12, 期 5, 页码 -出版社
WILEY
DOI: 10.1002/wrna.1648
关键词
chemotherapy resistance; nanocarrier; ovarian cancer; small interfering RNA; targeted therapy
类别
Ovarian cancer is the fifth leading cause of cancer-related death in women in the United States, with limited success in early screening and poor overall prognosis. Recurrence remains a major challenge in treatment. Understanding the pathogenesis of ovarian cancer is essential for developing more effective treatments.
Ovarian cancer is the fifth leading cause of cancer-related death in women in the United States. Because success in early screening is limited, and most patients with advanced disease develop resistance to multiple treatment modalities, the overall prognosis of ovarian cancer is poor. Despite the revolutionary role of surgery and chemotherapy in curing ovarian cancer, recurrence remains a major challenge in treatment. Thus, improving our understanding of the pathogenesis of ovarian cancer is essential for developing more effective treatments. In this review, we analyze the underlying molecular mechanisms leading to chemotherapy resistance. We discuss the clinical benefits and potential challenges of using nanocarrier-delivered small interfering RNA to treat chemotherapy-resistant ovarian cancer. We aim to elicit collaborative studies on nanocarrier-delivered small interfering RNA to improve the long-term survival rate and quality of life of patients with ovarian cancer. This article is categorized under: RNA Methods > RNA Nanotechnology Regulatory RNAs/RNAi/Riboswitches > RNAi: Mechanisms of Action
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据